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Three different conjugates having adriamycin (ADR) bound to the side chain carboxyl groups of 
high-molecular weight poly (a-L-glutamic acid) (PGA) either directly or by interpolation of GlyGly 
and GlyGlyGlyLeu spacers, respectively, were compared with respect to immunogenicity and cytotox- 
icity in mice as well as release of drug by lysosomal enzymes. The cytotoxic efficacy of a single i.p. dose 
of each conjugate (5 mg ADR-equiv./kg) against L1210 leukemia cells implanted i.p. in DBAz mice 
was studied by monitoring the survival time, the body weight and the number of long-term survivors 
(LTS ) . PGA-GlyGlyGlyLeu-ADR and PGA-GlyGly-ADR significantly enhanced the mean survival 
time (MST) of treated animals compared with the untreated control group (T/C 148- 149%) as did 
free ADR (T/C 147%). The tetrapeptide-spacer containing conjugate effected the presence of LTS at 
day50(2/5)asdidfreeADR(1/5). 
The secondary antibody response of the drug conjugates elicited in A/J mice after repeated dosage 
( 125 ,ug/mouse) at day 0, 14 and 28 was evaluated at day 35 using the ELISA technique. IgG titers 
varied from a very low value (PGA-GlyGlyGlyLeu-ADR) to moderately high levels (PGA-ADR, PGA- 
GlyGly-ADR) which are 2-3 orders of magnitude below that obtained for the strong immunogen bo- 
vine IgG. The data suggest hat certain parts on the surface of the conjugates are immunogenic. 
The release of extractable low-molecular weight products from the conjugates mediated by lysosomal 
enzymes was analyzed using reversed-phase HPLC. The release profile of ADR as well as Gly-ADR, 
Leu-ADR or GlyLeu-ADR was determined. The total amount of ADR released after 77 h was 3.6% for 
PGA-GlyGlyGly-Leu-ADR, 1 .O% for PGA-GlyGly-ADR and 0.5% for PGA-ADR. With all conjugates 
unidentified products were produced. 
It is proposed that the mechanism of action of the polymeric conjugates under in vivo conditions 
may be due to pinocytic capture followed by lysosomal degradation with release of ADR. 
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Introduction 
Delivery of cytostatic agents with the aid of 
soluble polymeric drug conjugates is a strategy to 
improve chemotherapy [ 11. The pharmacoki- 
netics and biodistribution of polymer-bound 
drugs will be different from those of the free drug. 
Generally, drug conjugates having molecular 
weights above the renal excretion limit may re- 
side in the body for prolonged periods. The re- 
lease of drug depends critically on the design of 
the drug-polymer bond. This bond can be 
adapted to be sensitive to slow hydrolytic cleav- 
age in the circulation yielding an approximately 
constant level of free drug for a prolonged period 
thereby suppressing drug-mediated toxic side ef- 
fects. Alternatively, macromolecular drug con- 
jugates are taken up by cells by the process of 
pinocytosis and drug release is occurring intra- 
cellularly due to the acidic environment in en- 
dosomal particles or the action of lysosomal en- 
zymes. To enhance specifically the intracellular 
degradation of the drug-polymer bond acid-sen- 
sitive linkers or lysosomally cleavable peptide 
spacers are used to link the drug with the carrier 
[ 11. Notably, the in vitro and in vivo biological 
properties in animals of conjugates of poly [ (2- 
hydroxypropyl)methacrylamide] , polyHPMA, 
and cytostatic agents have been studied by one 
of us (R.D.) extensively, including immunoge- 
nicity, biocompatibility, pharmacokinetics, 
biodistribution, pinocytosis, drug release by in- 
tracellular enzymes and cytotoxic effectivity 
~31. 
The cytostatic drug adriamycin ( ADR) is used 
intensively in the treatment of various tumors 
[ 41. Its main side effects are dose-limiting car- 
diotoxicity and myelosuppression [ 41. A major 
aim of delivering ADR with polymeric systems 
is to reduce the side effects of the drug by pre- 
venting peak concentrations of drug in the cir- 
culation and by effecting a selective delivery to- 
wards tumor cells. In previous papers we 
described the synthesis and in vitro properties of 
conjugates of ADR and biodegradable polymeric 
carriers derived from poly (a-L-glutamic acid) 
(PGA) [ 5-71. PGA is biodegradable, non-im- 
munogenic and non-toxic [ 8,9] and it allows the 
binding of drug via enzymatically or hydrolyti- 
tally labile bonds [ 1,10-l 21. Recently, we de- 
scribed the synthesis and biodistribution in mice 
of immunoconjugates of the human monoclonal 
antibody IgM 16.88 and the polymeric drug car- 
riers PGA and poly [N 5- (2-hydroxyethyl)-~-glu- 
tamine 1, PHEG [ 131. This study indicates the 
suitability of polyanionic PGA as well as un- 
charged PHEG for use as the drug carrier in im- 
munoconjugates. The ADR conjugates de- 
scribed previously [ 5-71 are designed to yield 
release of drug after pinocytic uptake by cells fol- 
lowed by lysosomal cleavage of the drug-poly- 
mer bond by using appropriate peptide spacers 
between carrier and drug but were not studied in 
vivo. 
The main purpose of the present paper is the 
study of immunogenicity and cytotoxicity against 
L12 10 leukemia cells in mice of PGA-derived 
ADR conjugates with different spacers between 
drug and carrier. The release of drug effected by 
lysosomal enzymes is described to allow corre- 
lation of biodegradability with in vivo cytotox- 
icity. The synthesis of new polymeric conjugates 
and of amino acid and peptide derivatives of 
ADR is described. 
Abbreviations 
ADR, adriamycin; BSA, bovine serum albu- 
min; CDI, N,N’-carbonyldiimidazole; CFA, 
complete Freund’s adjuvant; d, doublet; dd, 
double doublet; DCCI, NJV-dicyclohexylcarbo- 
diimide; DMF, N, N-dimethylformamide; 
DMSO, dimethylsulfoxide; DNM, daunomycin; 
DP,, number-average degree of polymerization; 
DP,, weight-average degree of polymerization; 
EDTA, ethylene diamine tetraacetate; EEDQ, N- 
ethoxycarbonyl-2-ethoxy- 1,2-dihydroquinoline; 
ELISA, enzyme-linked immunoassay; GlyGly- 
OBu’, glycylglycine tert-butyl ester; Gly-OBu’, 
glycine tert-butyl ester; GSH, glutathione (re- 
duced); HOAc, acetic acid; HONSu, N-hydrox- 
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ysuccinimide; HOBT, 1 -hydroxy~nzot~azole; 
HPMA, N- (2-hydrox~ropyl )methac~lamide; 
HP-SEC, high-performance size exclusion chro- 
matography; LALLS, low-angle laser light scat- 
tering; LTS, long-term survivors; m, multiplet; 
M,, number-average molecular weight; M,, 
weight-average molecular weight; MSA, metha- 
nesulphonic acid; MST, mean survival time; 
NCA, N-carboxyanhydride; Nh, ninhydrin; 
PBLG, poly ( y-benzyl-rglutamate); PBS, phos- 
phate-buffered saline; PGA, poly ( clll-L-gluta- 
mate); PHEG, poly [N 5- ( Z-hydroxyethyl )-L- 
glutamine]; PLG, ~-piperonyl-L-~utamate; PLG 
NCA, y-piperonyl+glutamate N-carboxyanhy- 
dride; PPLG, poly { (y-piperonyl)-a-rgluta- 
mate]; RH, spray reagent for detection of pep- 
tide bonds in TLC; s, singlet; SD, standard 
deviation; SE, standard error; SEC, size exclu- 
sion chromatography; THF, tetrahydrofuran; 
TFA, trifluoroacetic acid; TLC, thin-layer chro- 
matography; TMG, N,N,N’,N’-tetramethyl- 
guanidine; Trt, t~phenylmethyl; Trt-Gly, N-tri- 
phenylmethyl~y~ine; Trt-Gly-ONSu, N- 
t~phenylmethyl~ycine succinimidyl ester; Trt- 
Leu-OBT, N-t~phenylmethyl~ycine 1 -hydroxy- 
benzotriazole ester; Z-Gly, N-benzyloxy- 
carbonylglycine. 
Materials and Methods 
Materials 
Tetrahydrofuran (THF) and dioxane were re- 
fluxed overnight and distilled in the presence of 
sodium wire and benzophenone as an indicator. 
This procedure was repeated until development 
of a dark-blue color, indicating the absence of 
water. DMF was distilled in vacua and used im- 
mediately. N-ethylmorpholine and triethylam- 
ine were distilled from KOH. Trifluoroacetic acid 
(TFA) was distilled. 
The following compounds were obtained from 
the manufacturer indicated and were used as 
supplied. Nff-benzoyl-Phe-Val-Arg-~nitroani- 
lide, Serva, FRG, N-ethoxy~rbonyl-2-ethoxy- 
1,2-dihydroquino~ne (EEDQ), Serva, FRG; 
GlyLeu, Sigma, USA, GlyGlyLeu, Sigma, USA; 
glycine tert-butyl ester ( Gly-OBu’ ) , Serva, FRG; 
N-hydroxysuccinimide (HONSu ) , Janssen, Bel- 
gium; 1 -hydroxybenzotriazole ( HOBT ) , Sigma, 
USA, N-benzyloxycarbonylglycine ( Z-Gly ) , Sig- 
ma, USA. 
The following compounds were prepared as 
described. Glycylglycine tert-butyl ester hydro- 
chloride (HCl.GlyGly-0Bt.t’) [ 141; PGA-ADR 
[ 5 ] ; PGA-GlyGlyGlyLeu as described for PGA- 
GlyGlyLeu [ 5 ] ; PGA-GlyGlyGlyLeu-ADR as 
described for PGA-GlyGly~u-ADR f 5 ]; y-pi- 
~ronyl-L-~utamate ( PLG ) [ 15 ] ; y-piperonyl-L- 
glutamate N-carboxyanhyd~de (PLG NCA) 
f 16 1; N-t~phenylmethyl~ycine succinimidyl 
ester (Trt-Gly-ONSu) [ 171; N-triphenylme- 
thylglycine I-hydroxybenzotriazole ester (Trt- 
Leu-OBT) [ 181. 
Tritosomes were isolated from rat liver by a 
modification of the method of Trouet [ 19 ] as 
described by Kussendrager et al. [ 20 1. The tri- 
tosomes (0.52 mg/ml of protein) were about 70- 
fold purified in respect o the liver homogenate 
as determined by measuring the specific activity 
of acid phosphatase. 
Methods 
Analytical procedures 
‘H-NMR spectra were recorded on a Bruker 
WP 80 (80 MHz), a Nicolet 1280 (200 MHz) 
or a Bruker AC 250 (250 MHz). Chemical shifts 
(6) are given in ppm relative to tetramethylsi- 
lane; theoretical values of the number of protons 
of each signal are given between brackets. Thin- 
layer chromato~aphy (TLC) was performed on 
silica coated on plastic sheets GFzs4 (Merck, 
FRG) using the following solvent systems: A, 
chloroform/methanol (9515; v/v); B, chloro- 
form/methanol (9/ 1; v/v); C, chloroform/ 
methanol (8/2; v/v); D, chloroform/metha- 
nol/acetic acid (85/10/S; v/v); E, n-butanol/ 
acetic acid/water (4/ 1 /I; v/v). Spots were vis- 
ualized under UV-light, by spraying with Nh so- 
lution (Merck, FRG) followed by heating for 5- 
10 min at 110 *C for detection of amino groups, 
or by spraying with ~tolidine/~ (RN reagent) 
[ 2 I ] after chlo~nation for the detection of pep- 
tide bonds. 
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ADR concentrations were calculated from the 
absorbance at 490 nm using a molar absorbance 
coefficient of 8500 M-’ cm-‘. 
ADR and ADR-related extractable products 
from the degradation studies of ADR conjugates 
were analyzed by HPLC using a Lichrospher 100 
RP8 column ( 125 x4 mm; 5 ,um particle size) 
(Merck, FRG). The eluent was prepared by 
mixing water, acidified to pH 2.25 with per- 
chloric acid, and acetonitrile (70/30; v/v). A 
flow rate of 1 ml/min was used. The fhtores- 
cence of the column eluate was monitored at 560 
nm (& 488 nm) with a Perkin-Elmer LS-3 
spectrometer equipped with a HPLC flow cell. 
Elution profiles were assigned to ADR or its 
amino acid/peptide derivatives by spiking and 
by comparison of retention times. The amounts 
of ADR or assigned ADR derivatives were deter- 
mined from the peak height and extraction effr- 
ciency using a calibration curve. The retention of 
ADR or derivatives is expressed as k’ defined as 
&-to/to in which t, is the elution time of the com- 
pound of interest and to is the elution time of un- 
retarded compounds. 
Characterization of polymers 
Average molecular weights of poly [ (y-pipe- 
ronyl)-cx+glutamate] (PPLG) (1M,, M,) were 
determined by high-performance size-exclusion 
(HP-SEC) /low angle laser light scattering 
(LALLS) analysis using DMF as the eluent at a 
flow rate of 1 .O ml/min. The HP-SEC unit, con- 
sisting of a Waters model 6OOOA pump and a 
Waters U6K injector, was connected to three 
Waters ,uStyragel ( 105, 104, lo3 A) HPLC col- 
umns (7.8~300 mm) in series. The column 
eluate was monitored by a Chromatix KMX-6 
LALLS apparatus and a Waters R 401 differen- 
tial refractometer. Refractive index increments 
(dn/dc) at 633 nm were determined using a 
modified Brice-Phoenix BP-2000-V differential 
refractometer. The dn/dc value of PPLG was 
0.110 ml/g. 
The average molecular weight of PGA (K,) 
was determined by intrinsic viscosity measure- 
ments in 0.19 M NaCl, 10 mM sodium phos- 
phate, pH 7.3, using an Ubbelohde capillary di- 
lution viscometer or capillary micr~viscometer 
at 25 “C. The PGA molecular weight was calcu- 
lated from the intrinsic viscosity [q] and the re- 
lation [q] ~4.1 x 10e5x [JI~,]O.~~ [22]. 
The amount of piperonyl ester groups in PGA 
was determined from the UV spectra of solu- 
tions of PGA sodium salt in water using a molar 
absorbance coeffxcient of 3300 M-‘-cm-’ at 290 
nm [ 161. 
Synthetic procedures 
N-Ethylmorpholine (0.19 ml, 1.49 mmol) and 
Trt-Gly-ONSu (690 mg, 1.67 mmol) were added 
to a suspension of GlyLeu (280.3 mg, 1.49 
mmol) in DMF (4.0 ml). The mixture was 
stirred for 6 h at room temperature, TLC (sol- 
vent B) indicating complete conversion. Water 
(40 ml) was added and the pH was adjusted to 
8.5 with 7% NaHCO,. The solution was ex- 
tracted with ethyl acetate (4x 20 ml) and the 
aqueous layer was acidified to pH 2.5 with 1 N 
KHSO+ The mixture was extracted with ethyl 
acetate (4x 25 ml), the combined extracts were 
washed with water (4 x 8 ml), dried with Na2S04 
and evaporated to dryness in vacua. A solution 
of the remaining oil in ethyl acetate (11 ml) was 
slowly added with stirring to hexanes (mixed 
isomers, 70 ml), The precipitate was isolated by 
filtration, washed with hexanes and dried in 
vacua. Yield 547 mg (75%) of Trt-GlyGlyLeu, 
homogeneous on TLC (solvents B, C; Nh, RH). 
‘H-NMR ( DMSO-d6), consistent with the pro- 
posed structure: 60.88, d, 6.0 (6) H, Leu &CH3; 
6 1.57, m, 2.9 (3) H, Leu y-CH and Leu&CH,; 
62.69,s,2.3 (2) H,Gly-2CH,;63.80, d,2.3 (2) 
H, Gly- 1 CHI; 6 4.26, m, 1.2 ( 1) H, Leu cu-CH; 
6 7.34, m, 14 (15) H, trityl C6HS; 6 8.05, d, 1.0 
( 1) H, Leu NHCO; 6 8.26, t, 0.8 ( 1) H, Gly-2 
NHCO. 
GlyGlyGlyLeu 
~-Ethylmo~holine (0.93 ml, 7.3 mmol) and 
Trt-Gly-ONSu (3.04 g, 7.3 mmol) were added 
to a suspension of GlyGlyLeu ( 1.82 g, peptide 
content 85%, 6.3 mmol) in DMF ( 18 ml). The 
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mixture was stirred for 3 days at room tempera- 
ture and TLC indicating complete conversion. 
Water ( 100 ml) was added and the pH was ad- 
justed to 8.5 with 1 N NaOH. The solution was 
filtered and the clear filtrate was acidified to pH 
2.5 with 1 N KHSO,. The mixture was extracted 
with chloroform/methanol 9/l v/v (300 ml; 
3 x 100 ml), the combined extracts were washed 
with water (4 x 50 ml) and were evaporated to 
dryness in vacua. The residue was repeatedly 
evaporated to dryness in vacua after addition of 
methanol. A solution of the remaining oil in ethyl 
acetate (50 ml) was slowly added with stirring 
to hexane (mixed isomers, 500 ml) and stirring 
was continued for 15 h. The precipitate was iso- 
lated by ftltration and dried in vacua. Yield 3.56 
g of Trt-GlyGlyGlyLeu, practically homogene- 
ous on TLC (solvents B, C; Nh, RH) showing 
trace amounts of Trt-Gly. A solution of the prod- 
uct (2.2 g) in 75Oh acetic acid (30 ml) was stirred 
for 3 h at room temperature. Water ( 120 ml) was 
added and the solution was filtered. The clear fil- 
trate was evaporated to dryness in vacua and the 
residue was repeatedly evaporated to dryness in 
vacua after addition of methanol (2 x 50 ml) and 
toluene (4 x 50 ml ). A solution of the product in 
water ( 50 ml) was filtered (0.2 pm) and was ly- 
ophilized. Yield 938 mg of GlyGlyGlyLeu (pep- 
tide content 85%, 68% relative to GlyGlyLeu). 
Practically homogeneous on TLC (solvents D, E; 
Nh, RH) showing trace amounts of Gly. ‘H- 
NMR ( DMSO-d6, 6 in ppm relative to tetrame- 
thylsilane) consistent with the proposed struc- 
ture: 60.83, d, 5.9 (6) H, Leu &CH,; S 1.48, m, 
3.2 (3) H, Leu y_CH and &CH,; 6 3.41, s 
(broad), 2.1 (2) Hand 3.73, s (broad), 4.2 (4) 
H, various Gly CH2; S 4.1, m, 1 ( 1) H, Leu cy- 
CH; 6 7.50, d, 1.0 ( 1) H, Leu NH; 6 8.33, t, 1.0 
( 1) H, Gly NH; 6 8.73, s (very broad), 0.7 ( 1) 
H, Gly NH; the signal from the ammonium group 
was not observed probably due to fast exchange 
with HOD. The signals at S 7.50, 8.33 and 8.73 
disappear after addition to D20 confirming the 
exchangeability ofthe protons. Amino acid anal- 
ysis after acidic hydrolysis: Gly, 2.97; Leu, 1.04. 
L&.4-ADR 
Trt-Leu-OBT (92.9 mg, 0.190 mmol) was 
added to a stirred suspension of ADR (hydro- 
chloride) (99.9 mg, 0.172 mmol) in DMF (3.0 
ml) containing IV-ethylmorpholine (43.8 111, 
0.344 mmol). The mixture was stirred for 23 h 
at room temperature, TLC (solvent A) indicat- 
ing complete conversion, and the clear solution 
was evaporated to dryness in vacua. The residue 
was extracted twice with toluene/hexane l/2 
v/v (3 ml), the extract was discarded and the 
residue evaporated to dryness in vacua. The res- 
idue was purified by chromatography on a col- 
umn of silicagel ( 16 x 2.6 cm; particle size 40- 
63 pm) with chloroform/methanol 95/5 v/v as 
the eluent. Fractions containing the major prod- 
uct were pooled and evaporated to dryness yield- 
ing Trt-Leu-ADR ( 102 mg, 65%). The product 
was mixed with 75% acetic acid and stirred for 
2.5 h at room temperature, TLC (solvents D, E) 
indicating complete deblocking. Water ( 13 ml) 
was added and the precipitate was removed by 
filtration (Whatman GF/A). The pH of the fil- 
trate was adjusted to 8.5 with 1 N and 0.1 N 
NaOH with vigorous tirring and the mixture was 
extracted with chloroform/methanol 4/ 1 v/v 
(4 x 50 ml). The combined organic extracts were 
evaporated to dryness in vacua. Water (20 ml) 
was added and the vigorously stirred mixture was 
acidified to pH 3.5 with 0.1 N HCl. The solution 
was filtered (0.45 pm) and lyophilized yielding 
Leu-ADR (hydrochloride) (58.3 mg, 49%). 
Homogeneous on TLC (solvents D, E). M.p. 
175-178°C (dec.) (193”C, (dec.) [23]. ‘H- 
NMR (DMSO-de) consistent with proposed 
structure; characteristic signals: 6 0.89, dd, 5.7 
(6) H, Leu &CH,; 6 1.13, d, 3.0 (3) H, ADR 
CH&,;6 1.53,m, 3.3 (3) H,Leu&CH,andy- 
CH;S3.99,s, 3.0 (3) H,ADRCH30-C,;S8.10, 
s (broad), 2.0 (3) H, Leu NH3; S 8.33, d, 1.1 
( 1) H, ADR NHCO. 
Gly-ADR 
Gly-ADR (hy~ochlo~de) was prepared by 
reaction of TV-Gly-ONSu and ADR according 
to the procedure described for Leu-ADR. Yield 
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39%, homogeneous on TLC (solvents D, E). ‘H- 
NMR (DMSO-d,) consistent with the proposed 
structure; characteristic signals: 6 1.17, d, 2.9 (3 ) 
H, ADR CH&,; S 4.00, s, 3.1 (3) H, ADR 
CH,O-C,; 6 3.42, partly buried under the HZ0 
signal, Gly CH,; 6 8.12, s (broad), 2.3 (3) H, 
Gly NH,; S 8.30, d, 0.95 ( 1) H, ADR NHCO. 
GlyLeu-ADR 
GlyLeu-ADR (hydrochlo~de ) was prepared 
by reaction of To-Gly-ONSu and I&u-ADR ac- 
cording to the procedure described for Leu-ADR. 
Yield 57%, homogeneous on TLC (solvents D, 
E). ‘H-NMR (DMSO-de) consistent with the 
proposed structure; characteristic signals: S 0.88, 
dd, 5.4 (6) H, Leu SCH3; S 1.18, d, 2.8 (3) H, 
ADR CH,-C,,; S 1.45, m, 2.8 (3) H, Leu /3-CHl 
and Leu y_CH; 6 4.01, s, 3.3 (3) H, ADR CH30- 
Cq; 6 7.9-8.0, m, 5.4 (6) H, Gly-I NH3, Leu 
NHCG, ADR H-C1 and ADR H-C&; S 8.46, d, 
0.8 ( 1) H, ADR NHCO. The Gly CH2 signal is 
probably buried under the Hz0 signal at 6 3.35. 
iV,N-dicyclohexylcarbodiimide (DCCI) (45.7 
mg, 0.22 1 mmol) was added to a solution of Trt- 
GlyGlyLeu (105 mg, 0.215 mmol) and Why- 
droxysuccinimide (HONSu) (24.7 mg, 0.2 15 
mmol) in dichloromethane (0.8 ml) at 0°C. 
After 1.5 h TLC (solvent A) indicated almost 
complete conversion to the activated ester. The 
precipitate was filtered off, washed with dichlo- 
romethane and the filtrate was evaporated to 
dryness in vacua. The residue was dissolved in 
DMF (0.8 ml). N-ethylmorpholine (0.066 ml, 
0.052 mmol) and the solution of activated pep- 
tide ester (0.193 ml, 0.052 mmol) were added to 
a suspension of ADR (30.1 mg, 0.052 mmol) in 
DMF (0.5 ml). After a reaction time of 20 h at 
room temperature work-up of the mixture and 
removal of the trityl protecting group as de- 
scribed for Leu-ADR yielded GlyGlyLeu-ADR 
(hydrochlo~de) (36.9 mg, 79Oh). Homogene- 
ous on TLC (solvents D, E). ‘H-NMR (DMSO- 
d6) consistent with the proposed structure; char- 
acteristic signals: 6 0.84, dd, Leu S-CH,; 6 1.14, 
d, ADR CH,-C,,; S 1.43, m, Leu pCHz and Leu 
y-CH, 6 3.79, d, Gly- 1 or Gly-2 CH2; 8 4.00, s, 
ADR CH30-6,; 6 4.28, dd, Leu cu-CH, 6 7.65, m, 
Leu NHCO and ADR H-Cs; S 8.06, d, ADR 
NHCO; S 8.50, t, Gly-2 NHCO. 
PGA 
PGA was prepared by a procedure [ 161 which 
will be reported elsewhere. Briefly, y-( 3,4-meth- 
ylenediox yben~l )-L-glutamate ( Ppiperon yl-L- 
glutamate, PLG) [ 15 ] was converted to the N- 
~rboxy~hyd~de (PLG NCA) which was po- 
lymerized in dioxane (3 wt%) for 160 h at room 
temperature using triethylamine (A/I 50) as the 
initiator yielding poly [ (y-piperonyl)-L-gluta- 
mate], (PPLG) of it&, 244,000, DP, 927, J4, 
192,000, DP, 729, M,,,/M,, 1.27 as determined 
by HP-SEC/LALLS. PPLG was deprotected in 
trifluoroacetic acid/dichloromethane SO/SO v/v 
containing anisole [ 16 ] yielding PGA having a 
M, 73,000 (DP, 565) as determined by viscom- 
etry and a content of residual piperonylester 
groups of 0.10 mot%. 
PGA-ADR 
PGA-ADR was prepared as described earlier 
[51. 
PGA-GlyGiy-ADR 
N,N’ -~arbonyldiimidazole ( CD1 ) ( 436 mg, 
2.70 mmol) was added with stirring to a solution 
of PGA (259.1 mg, 2.01 mmol) and saccharinic 
acid (443 mg, 2.42 mmol) in DMF (5.0 ml) at 
room temperature. After 30 min a solution, pre- 
pared by dissolving HCl.GlyGly-OBu’ (473 mg, 
2.11 mmol) and N,N,N’,N’-tetramethylguani- 
dine (TMG) (0.265 ml, 2.11 mmol) in DMF 
(4.0 ml) was added. The reaction mixture was 
stirred for 4 days at room temperature and was 
added with stirring to sodium phosphate buffer, 
pH 7.0 (500 ml, 0.1 M). The precipitate was col- 
lected by filtration, washed with water ( 1 1) and 
dried in vacua yielding PGA-GlyGly-OBut (526 
mg, 86%). ‘H-NMR ( DMSO-de) was consistent 
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with the proposed structure, indicating a spacer 
load of 92 mol%. 
The brittle product (495 mg ) was cut in small 
pieces which were dissolved with stirring in tri- 
fluoroacetic acid (TFA) (7 ml). After 25 min 
the solution was evaporated to dryness in vacua 
and the residue was dissolved in sodium phos- 
phate buffer, pH 7.4 (20 ml, 0.25 M) by addi- 
tion of NaHC03 (7%) and NaOH ( 1 M) to ad- 
just the pH to 7.4. The solution was filtered 
(Whatman GF/A), dialyzed exhaustively 
against water at 4”C, filtered (0.45 pm) and ly- 
ophilized yielding PGA-GlyGly, sodium salt 
(399 mg, 88%). ‘H-NMR ( D20) was consistent 
with the proposed structure, indicating a spacer 
load of 97 mol% and a residual content of tert- 
butyl groups of 0.8 mol%. 
A solution of the polymer (202 mg) in water 
( 13 ml) was passed through a column of Dowex 
50 W X-8 (22 x 2.6 cm; pyri~nium form) using 
water as the eluent at a flow rate of 35 ml/h. The 
fractions containing polymer were pooled and 
lyophilized yielding PGA-GlyGly, pyridinium 
salt (185 mg), ADR (17.4 mg, 0.0300 mmol), 
N-ethylmorpholine (0.0076 ml, 0.0597 mmol) 
and a solution of EEDQ in DMF (0.072 ml, 
0.0360 mmol) were added to a solution of this 
carrier (170 mg, ca. 0.63 mmol) in DMF (2.4 
ml). The suspension was stirred for 3 days at 
room temperature in the dark. The red gel prod- 
uct was added to a mixture of sodium phosphate 
buffer, pH 7.4 (32 ml, 0.25 M) and NaHC03 so- 
lution (0.8 ml, 7%) and stirred until dissolution 
of the gel. The solution was dialyzed exhaus- 
tively against water at 4”C, filtered (0.45 pm) 
and lyophilized. A solution of the conjugate in 
water (35 ml) was passed through a column of 
Dowex 50 W X-8 (26~4.8 cm; sodium form) 
using water as the eluent at a flow rate of 30 ml/ 
h and the fractions containing the conjugate were 
pooled. The solution was filtered (0.2 pm) and 
lyophilized yielding PGA-GlyGly-ADR ( 12 1 mg, 
55%). 
PGA-G fyGlyGlyLeu-ADR 
PGA-GlyGlyGlyLeu-ADR was prepared as 
described for PGA-GlyGlyLeu-ADR [ 5 1. 
Degradation ofpolymer-bound ADR by lysosomal 
enzymes 
Degradation of polymer-bound ADR conju- 
gates or substrate was studied in a solution con- 
taining 0.10 M citric acid, 0.10 M disodium hy- 
drogen phosphate, 1mM EDTA buffer, adjusted 
to pH 5.50 with NaOH. 
The activity of the tbiol enzymes in tritosomes 
was determined by measuring the increase in UV 
absorbance at 410 nm due to release of pni- 
troaniline using N “-benzoyl-Phe-Val-Arg-pni- 
troanilide as the substrate according to Subr et 
al. [ 241. Specific activity was 0.025 dA&min 
per ml tritosome stock solution. 
Tritosomes (0.72 ml) were added to a solu- 
tion freshly prepared by mixing solutions of 
polymer-bound ADR (0.80 ml, 1 mg/ml in 
buffer), reduced glutathione (GSH) (0.40 ml, 
25 mM in buffer) and Triton X-100 (0.24 ml, 
5% in water). The mixture was incubated at 
37°C. After specified times a sample (0.10 ml) 
in a polypropylene tube ( 16x 100 mm) was 
mixed with 2 M ammonium formate buffer, pH 
8.50 (0.10 ml) and water (0.8 ml) [25]. Chlo- 
rofo~/2-propanol4/ 1 v/v (50 ml) was added 
and the mixture was shaken mechanically for 20 
min, using a horizontal position of the tube. After 
centrifugation (3000 rpm, 5 min) the aqueous 
layer was discarded and the organic layer was 
evaporated under a stream of nitrogen. The res- 
idue was dissolved in methanol (0. IO ml) con- 
taining daunomycin (DNM) ( 1 pg/ml) as the 
internal standard. The solution was analyzed by 
reversed-phase HPLC. 
Assessment ofi~un~nici~ by determining the 
antibody titres raised against PGA-derived 
carriers and ADR conjugates 
A/J female mice (5-8 weeks old) were main- 
tained in a constant environment for 2 weeks. 
The polymers were made up in Freund’s com- 
plete adjuvant (FCA) 1: 1 v/v as a water in oil 
emulsion and injected ( 125 pg/mouse) subcu- 
taneously (SC ) in mice maintained under halo- 
thane anaesthetic (5 mice per group). A group 
of control mice were injected with PBS and the 
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vehicle. After 14 days the mice received a second 
injection ( 125 pg polymer/mouse) intraperito- 
neally (i.p. ). In this case the polymer (2 ml of a 
1.1 mg/ml solution) was mixed with 200 ml of 
10% alum neutralized with 1 M NaOH. Four- 
teen days later this i.p. administration was re- 
peated. The mice were then exsanguinated 7 days 
later and the blood from each group of mice was 
pooled and allowed to stand overnight at 4°C. 
Sera were removed by aspiration following cen- 
trifugation (1000 xg, 10 min ) which pelleted the 
erythrocytes and the blood clot. The sera were 
subsequen~y stored at - 20 ’ C until required for 
enzyme-linked immunoassay (ELISA ) . 
The IgG and IgM in serum from polymer- 
treated and untreated control animals were de- 
termined by the ELISA technique. First the effi- 
ciency of antigen binding to the microtiter plates 
was determined in order to optimize the antigen 
coating concentration. For ELISA, assay micro- 
titer plates were coated with the polymer at a ti- 
nal concentration of 1 mg/ml (dissolved in 200 
~1 PBS and bound overnight at 4 * C ) . The plates 
were washed three times with 0.05% Tween 20 
in 0.9% NaCl in a Titertek plate washer. The sera 
(in 0.05% Tween 20/PBS) were serially diluted 
(2”fold or lo-fold as required) across the plate 
(final volume 150 ,ul ) and incubated at 37 ‘C for 
2 h. The initial sera dilutions were 1: 2 for IgM 
and 1: 1 O3 to lo4 for IgG. After washing the 
bound antibody as above, the plate was further 
incubated (2 h at 37°C) with peroxidase-linked 
goat anti-mouse IgM (p-chain specific) or IgG 
(y-chain specific) each diluted 1: 1000 in 0.05% 
Tween 2O/PBS. After further washing, 150 ~1 of 
the chromophore o~hophenylene~amine 
(0.04%) in phosphate-citrate buffer (pH 5.0) 
and peroxidase substrate (0.012% H202) was 
added to each well. After 15 min at room tem- 
perature the reaction was stopped with H2S04 
(75 ~;11,2 M ) and the absorbance at 492 nm mea- 
sured using a Titertek plate reader. 
Cytotoxicity of PGA-derived ADR conjugates 
against i-p. L1210 in mice 
Evaluation of ADR and PGA-derived ADR 
conjugates was carried out essentially as de- 
scribed in the National Cancer Institute Protocol 
[ 261. DBAz mice (males, 9112 weeks, 20-30 g) 
were inoculated i.p. at day 0 with 10s viable 
L 12 10 cells. ADR or polymeric ADR conjugates 
were administered i.p. at a single dose of 5 mg 
ADR-equivalents/kg at day 1. For each com- 
pound groups of five mice/compound were used. 
The animals were weighed daily, and observed 
twice a day for signs of tumor progression. The 
survival time and the number of long-term sur- 
vivors (LTS) at day 50 was monitored. 
Results 
Preparation of PGA-derived ADR conjugates 
Two types of polymer-bound ADR conjugates 
were prepared using the method described pre- 
viously [ 5 ] (Fig. 1, Table 1). In the first type 






PGA-ADR OH (Na) ADR 
PGA-GlyGly-ADR GiyGly GlyGly-ADR 
PGA-GlyGlyGlyLeu-ADR GlyGlyGlyLeu GiyGlyGlyLeu.ADU 
Fig. 1. Conjugates of PGA and ADR. 
TABLE 1 TABLE 2 
45 
Analytical data of PGA-derived ADR conjugates 
Conjugate Molecular Spacer ADR content 
weight. contentb 
(mole%) wt% mol% 
PGA-ADR 91,000 - a.2 2.5 
PGA-GlyGly-ADR 154,000 97 7.5 3.9 
PGA-GlyGlyGlyLeu-ADR 236,000 91 7.0 5.7 
“Theoretical weight-average molecular weight calculated from M, 
of PGA used and the composition as determined by ‘H-NMR. 
bRelative to Glu. 
ADR was linked via the aminoribosyl moiety 
with part of the carboxyl groups of PGA using 
EEDQ in DMF yielding the conjugate PGA-ADR 
with a drug content of 8.2 wt% as described [51. 
For the second type of conjugate PGA was grafted 
with the oligopeptides GlyGly or GlyGly- 
GlyLeu. PGA-GlyGlyGlyLeu was obtained by 
preactivation of the polymer with saccharin and 
CD1 in DMF and subsequent reaction of the sac- 
charin imides with the TMG salt of the oligopep- 
tide as described for PGA-GlyGlyLeu [ 5 1. PGA- 
GlyGlyGlyLeu contains 93 mol% of spacer 
groups relative to Glu residues. Due to the poor 
solubility of GlyGly in DMF, PGA-GlyGly was 
prepared by coupling of the C-terminal pro- 
tected peptide GlyGly-OBu’ onto PGA preacti- 
vated with saccharin and CD1 in DMF yielding 
PGA-GlyGly-OBu’ with a 91 mol% degree of 
substitution by spacer groups. The polymer- 
bound tert-butyl ester groups were removed by 
TFA treatment yielding PGA-GlyGly with 97% 
of spacer groups relative to Glu residues. 
ADR was coupled to part of the Gly or Leu 
carboxyl groups of the polymeric carriers using 
EEDQ in DMF yielding the conjugates PGA- 
GlyGly-ADR or PGA-GlyGlyGlyLeu-ADR with 
a drug content of 7.5 or 7.0 wt%, respectively. 
Preparation of amino acid and peptide derivatives 
of ADR 
The amino acid and peptide derivatives Gly- 
ADR, Leu-ADR, GlyLeu-ADR and GlyGlyLeu- 
ADR were prepared by the method of Masque- 
lier et al. [ 22,271 involving reaction of the 
Analytical data of amino acid and peptide derivatives of ADR 
Compound Extraction efficiency” k’ 
(SD) valueb 
(Oh) 
ADR 57 (6.4); 54 (1.7)’ 
HCl.Gly-ADR 33 (3.4) 
HCl.Leu-ADR 32 (3.8) 
HCl.GlyLeu-ADR 28 (2.6) 
HCl.GlyGlyLeu-ADR 
BFrom buffer solution. 
bin reversed-phase HPLC (see Methods). 






HONSu or HOBT ester of N-triphenylmethyl 
(Trt ) protected amino acid or peptide with ADR 
in DMF (Table 2). The N-protected ADR deriv- 
atives were purified from minor side products by 
column chromatography on silica using chloro- 
form/methanol as the eluent and the Trt pro- 
tecting group was removed by reaction in 75O/b 
acetic acid for 3 h at room temperature yielding 
the amino acid or peptide derivatives of ADR as 
hydrochlorides in overall yields of 39-79%. The 
final products were found to be homogeneous as 
judged from reversed-phase HPLC and from ‘H- 
NMR. TLC and normal-phase HPLC indicated 
the presence of trace amounts of aglycone 
products. 
Release of ADR and extractable drug-related 
compounds from polymeric ADR conjugates by 
lysosomal enzymes from rat liver 
To study the release of drug and drug-related 
compounds the conjugates PGA-ADR, PGA- 
GlyGly-ADR and PGA-GlyGlyGlyLeu-ADR 
were incubated with lysosomal enzymes from rat 
liver (tritosomes) in 0.1 M citric acid/sodium 
phosphate buffer, pH 5.5, at 37°C. At specified 
incubation times up to 77 h a sample from each 
incubation mixture was mixed with 1 M ammo- 
nium formate buffer, pH 8.5, and extracted with 
chloroform/2-propanol 4/ 1 v/v. The organic 
extracts were evaporated to dryness, the residue 
was dissolved in methanol containing DNM as 
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Elution time fmin) 
Fig. 2. Reversed-phase HPLC analysis of fluorescent extractabie products obtained after incubation of PGA-derived ADR con- 
jugates for 46 hat 37°C in the presence or absence of lysosomal enzymes. The incubation mixtures fpH 5.5 ) ~~ntain~po~ymer- 
bound ADR, 0.37 mg/ml of conjugate; reduced glutathione, 4.6 mM, T&on X-100,0.55 wt’& citric acid, 0.1 M, sodium phos- 
phate, 0.1 M; EDTA, 1 mh4; lysosomal enzymes (not in controls), OS17 mg/ml of protein. 
lyzed by reversed-phase HFLC using fluores- traction efficiencies determined (Table 2). No 
cence detection of ADR and ADR-related prod- corrections were made for the decomposition of 
ucts. The conjugates were also incubated in the ADR and extractable derivatives during the in- 
absence of enzymes to assess the release of ex- cubation period. 
tractable products by non-enzymatic processes. Cbromatograms obtained at 46 h incubation 
The data were corrected for the loss of com- time are shown in Fig. 2. Part of the peaks were 
pound in the extraction process by using the ex- assigned by comparison with ADR and the pro- 
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F&J. 3. Time dependence ofrelease of ADR titer incubation 
ofpGA-derived ADR conjugates with IysosamaI enzymes (3’) 
or in buffer (C). 
drugs Gly-ADR, Leu-ADR, GlyLeu-ADR and 
GlyGlyLeu-ADR (Table 2 ). The time depen- 
dence of the release of ADR or of various as- 
signed products released is plotted in Figs. 3 and 
4, rt;spectively, 
In the presence of tritosomes PGA-ADR is de- 
graded to yiefd one major extritctab~e product 
(X,) other than ADR but of unassigned struc- 
ture, Small amounts of ADR (ca. 0.5% after 20 
h ) and another product (X,) are present. III the 
control soWion without enzymes trace amounts 
of ADR are present, the increase with time indi- 
catiug that the polymer-drug band in the directly 
Kg, 4. Time dependence of rekase of ADR and ADR deriv- 
atives after incubation of PGA-detiv& ADR conjugates with 
lysasomai enzymes (T ) or in buffer (C)* 
coupled conjugate is very slowly cleaved by 
chemical hydrolysis, In the presence of trito- 
somes PGA-GlyGlywADR yields two products in 
significant amounts, one of which is assigned to 
ADR and the other (X3) is of unknown strut- 
ture. Trace amounts of Gly-ADR were aSso ob- 
served. The amounts of ADR or Gly-ADR are 
similar whether tritosomes are present or not, at 
aB time int~vals studied, indicating slow chem- 
ical hydroiysis of polymer-buund drug, PGA- 
GlyGlyGlyLeu-ADR yields various products in 
the presence of tritosomes including ADR, Leu- 
ADR, GfyLeu=ADR and G~yGly~u-ADR as well 
as unknown compounds (X,, X5) as has been 
found earlier [ 7 ‘j . The initial release of GlyLeu- 
ADR (3.5% at 4 h) and Leu-ADR (9% at 20 h) 
is relatively fast, while the release of ADR in- 
creases lowly fern 0.5% at 4 h to 3S% at 77 h. 
Insignificant amounts of GlyGtyLeu-ADR, 
which practicz&y coaelutes with DNM, were 
found. The total amount of ADR, Leu-ADR and 
GlyLeu-ADR present at 20 h ( 11%) decreases 
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on further incubation. This may indicate decom- 
position of the compounds but this was not fur- 
ther investigated. Small amounts of ADR (0.5- 
0.8%) are released in buffer solution both at the 
start of the experiment and later on. This can be 
explained by the presence of ADR as a contami- 
nant in the conjugate preparation and by the oc- 
currence of chemical hydrolysis of polymer- 
bound drug. 
Immunogenici~ ofADR conjugates 
The drug conjugates PGA-ADR, PGA-GlyGly- 
ADR and PGA-GlyGlyGlyLeu-ADR as well as 
the carrier polymer PGA-GlyGlyGlyLeu were 
studied for their ability to induce an antibody re- 
sponse in A/J female mice. The materials were 
administered to groups of 5 mice at a dose of I25 
,ug/mouse as a 1: 1 mixture with Freund’s com- 
plete adjuvant (FCA) on day 0 (SC) and at the 
same complete dose as an alum precipitate on day 
14 (i.p. ) and day 28 (i.p. ). On day 35 the blood 
was collected and the titers of immunogen-spe- 
cific IgG and IgM were determined with horser- 
adish peroxidase-labeled anti-IgG and anti IgM, 
respectively, by the ELISA technique as de- 
scribed previously [ 281. The results are col- 
lected in Table 3. 
Appreciable titer values (800,000 units-’ ) 
were found with PGA-ADR and PGA-GlyGly- 
ADR indicating that these drug conjugates are 
TABLE 3 
Antibody titers raised against poly(~-L-~utamic acid) and 
adriamycin derivatives after repeated administration to A/J 
female mice (n = 5) in Freund’s complete adjuvant and alum’ 
Compound Titer-’ 
I& IiN 
Control (PBS+FCA) 0 (0) 0.02 (0.01) 
PGA-GlyGlyGlyLeu 0 (0) 0.07 (0.03) 
PGA-ADR 8.14 (1.63)X 105 0.05 (0.02) 
PGA-GlyGly-ADR 8.14 (1.63)x lo5 0.03 (0.02) 
PGA-GlyGlyGlyLeu-ADRb 0.04 (0.02) 0.03 (0.02) 
‘Titres for IgG and IgM are mean values ( rt SE) of three sep- 
arate ELISA assays. 
bAnimats showed signs of ADR toxicity. 
immunogenic. The titer values are lower in mag- 
nitude by 2-3 orders of ten compared with the 
titer found after administration of the strong im- 
munogen bovine IgG to A/J mice [ 281 and the 
ADR conjugates may thus be classified as mod- 
erately strong immunogens. In contrast, the drug 
conjugate PGA-GlyGlyGlyLeu-ADR generates a 
very low level of antibodies (titer value 0.04) 
while no antibodies were detected with the car- 
rier polymer PGA-GlyGlyGlyLeu. For all mate- 
rials the level of IgM antibodies at day 35 is low 
(titer values 0.02-0.07) in agreement with the 
usual time dependence of the IgM response to 
immunogens. 
In vivo cytotoxicity of ADR conjugates 
PGA-ADR, PGA-GlyGly-ADR and PGA- 
GlyGlyGlyLeu-ADR were compared for their 
capability to suppress the growth of L 12 10 cells 
implanted intrape~toneally in DBAz mice. A 
single dose (5 mg ADR-equivalents/kg) of each 
polymeric ADR conjugate as well as free ADR 
was administered i.p. on day 1 using groups of 5 
mice and the survival time, the mean body weight 
and the LTS were monitored. The results are 
given in Table 4 and Figs. 5 and 6, respectively. 
Untreated animals show a steady increase in 
body weight for 9-10 days after tumor inocula- 
tion due to tumor growth and die at 12.6 days. A 
single dose of free ADR administered on day 1 
suppresses the tumor growth significantly up to 
day 12- 13 as shown by the reduced increase of 
the body weight, the enhanced value of the MST 
TABLE 4 
Effect of i.p. administration of PGA-ADR conjugates on DBA? mice 
(n=5) bearing 10s LIZ10 cells rnoculated i.p. on day 0 (dose 5 mg 










Controls 11,13,13,13,13 12.6 (0.4) - o/5 
ADR 35,16,21,22 18.5 (1.8) 147 l/5 
PGA-ADR 14,14,14,14,i4 14.0 (0) Ill o/s 
PGA-GIyGly-AIR 14,14,18,24,24 18.8 (2.2) 149 O/5 
PGA-GlyGlyGly~u-ADR 15, t7,24 18.7 (2.7) 148 2/5 
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Fig. 5. Effect of treatment of DBA, mice carrying i.p. L1210 
with ADR or PGA-derived ADR conjugates on survival. 
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Fig. 6. Effect of treatment of DBAz mice carrying i.p. L1210 
with ADR or PGA-derived ADR conjugates on body weight. 
( 18.5 days) and the presence of LTS at day 50 
( l/5), Animals treated with PGA-ADR at day 1 
show an increase in body weight and MST ( 14.0 
days) very similar to the data of the untreated 
control group indicating that this conjugate is 
therapeutic~y ineffective. PGA-GlyGly-ADR 
does not suppress the initial tumor growth as 
shown by the increase in body weight during the 
first period of 12- 13 days. After day 12- 13 a de- 
cline in body weight is seen. Consistently, the 
MST of animals treated with PGA-GlyGly-ADR 
(18.8 days) is larger than that of the control 
group ( 12.6 days) indicating a definite thera- 
peutic effect comparable to free ADR although 
no LTS at day 50 were observed. The body weight 
of animals treated with PGA-GlyGlyGlyLeu- 
ADR shows a modest increase up to day 12- 13 
followed by a decrease up to day 24 and an in- 
crease thereafter. The MST of 18.7 days is simi- 
lar to that found for PGA-GlyGly-ADR or ADR 
and 2 out of 5 animals survive at day 50. These 
data indicate that PGA-GlyGlyGly~u-OR is 
a therapeutically active conjugate. Qualitatively, 
the order of ADR conjugates with respect o in 
vivo antitumor action is PGA-GlyGlyGlyLeu- 
ADR z ADR > PGA-GlyGly-ADR=sPGA-ADR. 
Discussion 
Release of ADR from polymeric onjugates 
The release of ADR and the release as well as 
the nature of extractable ADR derivatives me- 
diated by lysosomal enzymes acting on PGA- 
ADR, PGA-GlyGly-ADR and PGA-GlyGly 
GlyLeu-ADR is obviously strongly affected by 
the conjugate structure, especially the presence 
and composition of a peptide spacer between 
drug and carrier. PGA-GlyGlyGlyLeu-ADR is 
degraded to an appreciable xtent yielding drug 
and low-molec~~ weight drug-spacer frag- 
ments, notably GlyLeu-ADR and Leu-ADR. The 
enzymatic degradation is probably mediated by 
the endopeptidase action of lysosomal protei- 
nases such as cathepsin B, L (both thiol-depen- 
dent) and D in combination with the exopepti- 
dase action of lysosomal dipeptidases, including 
the thiol-dependent cathepsin C, and aminopep- 
tidases, including the thiol-dependent cathepsin 
H [ 29,30 1, The presence of the drug derivatives 
GlyLeu-ADR and Leu-ADR in addition to ADR 
indicates that the GlyGlyGly~u spacer pro- 
vided a rather low specificity in the lysosomal 
degradation. On the other hand, spacers yielding 
highly specific tritosome-mediated ADR release 
from polymeric conjugates contain two or more 
hydrophobic amino acids which, when grafted 
onto PGA, would yield a rather hydrophobic 
carrier. In turn, substitution of such a hydropho- 
bic carrier by the very hydrophobic ADR moiety 
probably results in strong associative phenom- 
ena or insolubility. Thus, the GlyGlyGlyLeu 
spacer provides a compromise between solubil- 
ity of the drug conjugate and lysosomal degrad- 
ability of the drug-carrier linkage. PGA-GlyGly- 
ADR yields trace amounts of ADR increasing 
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with time either in the presence or absence of tri- 
tosomes. This indicates that slow chemical hy- 
drolysis of the drug-polymer bond occurs pre- 
sumably due to a catalytic effect of neighbouring 
polymer-bound carboxyl groups or of buffer 
components. Apparently, one product of as yet 
unassigned structure is produced from PGA- 
GlyGly-ADR by the action of lysosomal en- 
zymes. The absence of any ADR release from 
PGA-GlyGly-ADR attributable to the action of 
lysosomal enzymes agrees with earlier data on 
polyHPMA conjugates of GlyGly-DNM show- 
ing complete stability of the polymer-bound rug 
towards tritosomes [ 3 11. Trace amounts of ADR 
are also produced from PGA-ADR conjugates 
either in the presence or absence of tritosomes 
apparently due to chemical hydrolysis of the 
polymer-bound rug. Tritosomes effect the re- 
lease of one product from PGA-ADR in signifi- 
cant amounts but its structure is as yet unknown. 
In summary, the rate of ADR release from po- 
lymeric conjugates mediated by tritosomes can 
be regulated by the use of an enzymatically 
cleavable spacer. Chemical hydrolysis of the 
drug-polymer bond is also observed but seems of 
minor importance. 
Immunogenicity ofADR conjugates 
In order to be therapeutically effective, poly- 
mer-bound cytostatics hould remain in the cir- 
culation for prolonged time periods. When con- 
jugates are immunogenic, rapid capture by 
macrophages or inflammatory reactions may oc- 
cur especially after repeated administration by 
which the immune response is enhanced. These 
events are generally undesirable although cap- 
ture by and degradation in macrophages may 
contribute to cytotoxicity towards target cells in 
some cases. 
PGA-derived ADR conjugates were adminis- 
tered using sustained-release dosage forms with 
FCA and alum, which also stimulate the im- 
mune system. These conditions are a strong chal- 
lenge for the immune system. The immune re- 
sponse obtained may not always be 
representative for therapeutic administration. A
moderate dose was given threefold with a fre- 
quency of 14 days to reduce the possible contri- 
bution of immunologic paralysis [28 1. The mag- 
nitude of the secondary (IgG) antibody response 
elicited by PGA-derived drug conjugates in A/J 
mice at day 35 is clearly dependent on the chem- 
ical structure of the conjugates (Table 3 ). Exten- 
sive studies have been performed on the immu- 
nological properties of poly ( a-L-amino acids), 
vinyl polymers and natural macromolecules in- 
cluding dextrans and proteins as well as carrier- 
bound haptens uch as chromophores, drugs and 
nucleotides [ 32-35 1. From these studies general 
rules governing immunogenicity of materials 
have been deduced. Homopolymers including 
PGA generally show no or only a weak immu- 
nogenicity which has been explained by the flex- 
ibility of the polymers in aqueous olution and 
the homogeneous urface due to the repeating 
nature of the chemical structure. When the pri- 
mary structure of the macromolecule is more 
complicated such as in block and graft copoly- 
mers or polymers carrying haptens, various parts 
of rather small molecular dimensions on the ma- 
cromolecule (epitopes) may induce the forma- 
tion of complementary antibodies presumably 
due to the heterogeneity of the surface. Notably, 
ADR bound to BSA has been found to be im- 
munogenic and monoclonal antibodies directed 
against different parts of the ADR moiety have 
been isolated indicating that ADR can act as a 
hapten [ 361. Thus, the immunogenicity of PGA- 
ADR and PGA-GlyGly-ADR might be well due 
to the drug moiety. Although PGA has been 
found previously to be non-immunogenic, the 
monomer units may become immunogenic in the 
PGA-ADR conjugate as found previously for 
HPMA copolymers [28 1. The immunogenicity 
of the PGA-GlyGly-ADR conjugate may be due 
to the glutamine backbone units, the drug as al- 
ready mentioned, or to the spacer which has been 
found previously to act as an epitope when bound 
to polyHPMA [ 28 1. The absence of immunoge- 
nicity of PGA-GlyGlyGlyLeu and the ADR con- 
jugate suggests hat neither the carrier, spacer nor 
drug acts as an epitope. Due to the method of 
antibody detection used in the present study, the 
absence of immunogenicity of PGA-GlyGly- 
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GlyLeu-ADR might theoretically be due to cy- 
totoxic effects of free ADR after degradation of 
the conjugate prior to presentation to immuno- 
competent cells. A very low antibody response to 
conjugate of ADR bound through a biodegrada- 
ble GlyPheLeuGly spacer to polyHPMA has been 
found previously [ 371. The viability of the im- 
munocompetent cells was found unimpaired as 
measured by the antibody response against sheep 
red blood cells simultaneously administered with 
ADR conjugate. Nevertheless, a more detailed 
study on the effect of PGA-derived conjugates on 
the state of the immune system seems warranted 
in view of the different conjugate structure and 
the use of adjuvant in our case. 
Cytotoxicity of ADR conjugates 
The in vivo efficacy of PGA-derived ADR 
conjugates against L 12 10 tumour cells is depen- 
dent on the chemical structure. PGA-ADR is to- 
tally ineffective. PGA-GlyGlyGlyLeu-ADR and 
PGA-GlyGly-ADR enhance the mean survival 
time of treated animals significantly relative to 
the untreated control group. The GlyGly- 
GlyLeu-containing conjugate is the most effec- 
tive as shown by the presence of long-term sur- 
vivors at day 50 which was observed for free 
ADR as well but not with the GlyGly-containing 
conjugate. The cytotoxic efficacy of the PGA- 
GlyGlyGlyLeu-ADR is consistent with the rela- 
tively fast rate of tritosomes-mediated release of 
ADR pointing to in vivo release of free drug in 
lysosomal compartments. However, the cyto- 
toxic effectivity of the GlyGly and GlyGly- 
GlyLeu conjugates does not surpass that of free 
ADR on the basis of total drug administered. In 
this study a single dose of each of the conjugates 
was administered and repeated osage would be 
expected to enhance the cytotoxicity. For a more 
definite assessment of the therapeutic potential 
of the PGA-bound conjugates tudies on phar- 
macodynamics and on drug-related side effects, 
notably cardiotoxicity, will be needed. 
It has been found in previous studies that the 
growth of L12 10 cells in vitro by PGA-derived 
ADR conjugates having GlyGlyLeu and Gly- 
GlyGlyLeu spacers was inhibited only at high 
doses of conjugates [6,7]. This was tentatively 
explained by inefficient uptake by and/or deg- 
radation in the cells [ 6,7]. Thus, the significant 
in vivo antitumor activity of GlyGlyGlyLeu- 
containing ADR conjugate against L 12 10 cells 
found in the present study is not anticipated from 
the in vitro data. In our recent study on the bio- 
distribution of immunoconjugates of PGA and 
PHEG after iv. administration to mice a high 
uptake of free PGA in liver and a very low level 
in blood was found [ 131. The RES targeting of 
PGA may be well due to the anionic charge of 
the polymer similar to other polyanions [38 1. On 
this basis the ADR conjugates when adminis- 
tered i.p. might be taken up efficiently by peri- 
toneal macrophages, in which then lysosomal 
degradation can occur, and free ADR may dif- 
fuse out of the macrophages. Thus the fate and 
processing of ADR conjugates may be similar to 
that of i.p. administered ADR-containing lipo- 
somes [ 391. 
The high cytotoxic effectivity of the PGA- 
GlyGly-ADR conjugate is not expected in view 
of the very low rate of ADR release observed in 
solution either in the presence or absence of tri- 
tosomes. At present we speculate that the cyto- 
toxicity of PGA-GlyGly-ADR conjugate might be 
due to mechanisms other than those effected by 
free drug. For instance, the polymer-bound rug 
might mediate cytotoxic effects by interaction 
with the target cell membrane as has been pro- 
posed earlier to explain the in vitro cytotoxicity 
of polyHPMA carrying DNM bound to the non- 
degradable GlyGly spacer [ 401. This effect was 
not noticeable in vivo for conjugates of poly- 
HPMA and GlyGly-DNM or GlyGly-ADR, 
which were found totally inactive [ 3,4 11, thus 
contrasting with the present results. On the basis 
of the immunogenic nature of the PGA-GlyGly- 
ADR conjugate we include the possibility that 
biological defense mechanisms are activated. 
Conclusions 
PGA-GlyGlyGlyLeu-ADR conjugate having a 
lysosomally cleavable spacer enhances the sur- 
52 
vival time of mice carrying i.p. L12 10 tumor cells 
after a single i.p. dose of conjugate. 
The cytotoxicity of this conjugate is probably 
due to release of ADR mediated by lysosomal 
enzymes and may well occur in RES cells. 
The antitumor activity of PGA-GlyGly-ADR 
has to be explained by mechanisms not yet 
established. 
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